AlloASCT is considered the standard treatment for many hematological malignanices. The availability of a donor is of concern considering that almost half of Caucasian patients have a HLA-identical sibling or matched unrelated donor. Alternative nonidentical donors such as cord blood or haploidentical-related donors could expand the accessibility of alloSCT for all patients. Recently, encouraging results have been obtained using haploidentical-related donor, nonmyeloblative (NMA) regimens, T-replete BM and post-transplantation CY. 1 High dose, posttransplantation CY administered at fixed time after BM infusion, is supposed to kill alloreactive donor and host T cells, activated by respective antigens, thus reducing the incidence of GVHD and host vs graft reaction. 2 In order to reduce the incidence of infections and relapse incidence in high-risk patients, we decide to treat patients with acute GVHD (aGVHD) by extracorporeal photochemotherapy (ECP) as first-line therapy avoiding long-term steroid administration.
The aim of this report was to evaluate and describe the course of patients with aGVHD treated by ECP in a steroid-free protocol.
Starting from 2009, we launched a haploidentical program, using NMA/reduced intensity conditioning regimen (RIC), T-replete BM and post transplantation CY. Since this time, 40 patients have been grafted and their characteristics are reported in Table 1 .
Conditioning regimen consisted of CY 14.5 mg/kg on days À 5 and À 6, fludarabine 30 mg/m 2 from days À 6 to À 2 and lowdose TBI (2 Gy) at day À 1. For six patients, the conditioning regimen consisted of thiotepa 10 mg/kg on day À 6, fludarabine 30 mg/m 2 from days À 5 to À 2, CY 30 mg/kg on days À 5 and À 4 and low-dose TBI (2 Gy) at day À 1. GVHD prophylaxis was identical for both NMA/RIC and consisted of CY 50 mg/kg on days þ 3 and þ 4, tacrolimus (1 mg total dose, in continuous infusion) until days þ 180 and MMF (15 mg/kg three times per day) until day þ 35. Tacrolimus was started at day þ 5. G-CSF was started at day þ 5 in all patients.
Acute GVHD diagnosis was performed using Keystone criteria 3 and scored by Seattle and IBMTR criteria. Skin biopsy was not systematically performed. ECP was performed using the offline technique. 4 Briefly, MNCs were collected from the patient using a cell separator device and then irradiated (UV-A at 2 J/cm 2 ) in the presence of 8-methoxypsoralen (at a concentration of 200 ng/mL). Finally, the photoactivated MNCs were reinfused into the patient.
ECP was started as soon as possible after aGVHD diagnosis. The ECP treatment schedule consisted of four rounds of two procedures per week, three rounds of two procedures every other week and finally two procedures every month until clinical improvement and/or immunesuppressive therapy (IST) tapering. Decision to discontinue ECP was made on a case-by-case basis, taking into account clinical response (including IST changes), logistical reasons and the decision of the treating physician.
Forty patients were included in the analysis. Thirty-five patients (81%) were evaluable for aGVHD. Eight patients were not evaluable because of early deaths.
Acute GVHD any grade was diagnosed in 13 patients (37%). The incidence of grade 2-4 aGVHD was 29% (n ¼ 10). In these patients, all but one had grade 2 skin aGVHD. Only one patient was diagnosed as grade 4 liver plus skin aGVHD. The median time of aGVHD diagnosis was 52 days (range 38-81). These patients were included in the present analysis.
Seven patients were treated with ECP as first-line treatment, whereas three patients received steroids alone, because of logistical problems to start ECP. ECP was started after a median time of 3 days (range 1-30) from aGVHD diagnosis. For three patients, waiting for ECP, steroids therapy at dose of 1 mg/kg/day was started and withdrawn within 1 week. The median number of ECP performed was 15 (9-44) and the median duration was 99 days (40-368).
Complete response was observed in six out of seven patients (90%) and one patient achieved PR. The median time to obtain CR/PR was 14 days (range 2-57).
Tolerance to ECP was good and no patients developed severe toxicities. Two (18%) out of ten patients developed chronic GVHD: one severe and one moderate by National Institutes of Health score system.
At last follow-up, two patients died: one from heart failure secondary to hemochromatosis and one from disease progression. Three patients relapsed after a median time of 133 days (range 123-162). Relevant clinical characteristics of patients treated with ECP are shown in Table 2 . This observational study suggests that ECP without steroids is safe and effective first-line treatment for aGVHD after haploidentical transplantation.
All patients were grafted for high-risk disease using T-cell replete BM and post-transplantation CY, as described by Luznik and co-workers. 1 In their initial study, using a nonmyeloablative conditioning regimen, they reported grade II-IV aGVHD incidence of 34% and steroids therapy 1 or 2 mg/kg was used for all patients.
Concerned by the high risk of infectious complications with steroid therapy, we decide to treat patients with aGVHD using a steroid-free program based on ECP. This treatment was effective in all patients, and no progression or loss of response was observed during the follow-up and only two patients developed chronic GVHD. It should be pointed out that patients treated with ECP in this study had aGVHD limited to skin without visceral involvement. This selection of good prognosis patients could partially explain the excellent results.
The place of ECP in the treatment of aGVHD is usually reserved as second or further line, after steroids failure. In this poor prognosis setting, ECP performed well and the CR rate range from 52 to 72%. [5] [6] [7] [8] In the literature, no data have been reported extensively on the use of ECP as first-line therapy for aGVHD, and even less in the field of haploidentical transplantation.
In conclusion, although this is a retrospective small not controlled study with inherent selection bias, ECP should be considered as first-line treatment of aGVHD after haploidentical transplantation, to reduce the use of steroids. Probably, this approach is most effective and safe in grade II aGVHD. These results have to be confirmed in a more consistent number of patients. 
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